HEALTH TECHNOLOGY ASSESSMENT, PRICE AND REIMBURSEMENT REVIEW FOR ORPHAN DRUGS IN ITALY

被引：1
|
作者：
Tavella, F. [1 ]
Korchagina, D. [2 ]
Rodrigues, J. [2 ]
Remuzat, C. [2 ]
机构：
[1] Creativ Ceut, London, England
[2] Creativ Ceut, Paris, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1733
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY103
引用
收藏
页码：A540 / A540
页数：1
相关论文
共 50 条
  • [31] Authorization and Reimbursement of Orphan Drugs in an International Comparison
    Roll, K.
    Stargardt, T.
    Schreyoegg, J.
    GESUNDHEITSWESEN, 2011, 73 (8-9) : 504 - 514
  • [32] AVAILABILITY AND REIMBURSEMENT OF ORPHAN DRUGS IN THE CZECH REPUBLIC
    Ornstova, E.
    Sebestianova, M.
    Paris, M.
    Mlcoch, T.
    Bartakova, J.
    Chadimova, K.
    Hajickova, B.
    Dolezal, T.
    VALUE IN HEALTH, 2018, 21 : S461 - S461
  • [33] Orphan drugs: pricing, reimbursement and patient access
    Barak, Adam
    Nandi, Jyoti Shankar
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING, 2011, 5 (04) : 299 - 317
  • [34] ELIGIBILITY OF ORPHAN DRUGS FOR PREFERENTIAL REIMBURSEMENT IN EGYPT
    Fasseeh, A. N.
    Elezbawy, B.
    Korra, N.
    Roushdy, M.
    Seyam, A.
    Hayek, N.
    Rahman, Abdel N.
    Abdelhamid, S.
    Fasseeh, N.
    Saad, A. S.
    Elagamy, A.
    Mahmoud, A.
    Sedrak, A. S.
    Elshazly, K.
    Eldebeiky, M.
    Talaat, M.
    Maher, N.
    Abdelaziz, R.
    Refaat, R.
    Akeel, S.
    Adel, R.
    Khalil, S.
    Abaza, S.
    Kalo, Z.
    VALUE IN HEALTH, 2022, 25 (12) : S265 - S265
  • [35] UNDERSTANDING THE ROLE OF REAL-WORLD EVIDENCE IN HEALTH TECHNOLOGY ASSESSMENT FOR ORPHAN DRUGS
    Akesson, C.
    Llewellyn, S.
    Bagshaw, E.
    Kousoulakou, H.
    Larkin, M.
    VALUE IN HEALTH, 2019, 22 : S862 - S862
  • [36] ANTIOSTEOPOROTIC DRUGS AND THEIR REIMBURSEMENT IN ITALY
    Nuti, R.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S57 - S58
  • [37] HEALTH TECHNOLOGY ASSESSMENT (HTA) REVIEW OF CELL & GENE THERAPIES: THE ROAD TO REIMBURSEMENT
    Vu, B. K.
    Forsythe, A.
    Nguyen, K.
    Tomaras, D.
    VALUE IN HEALTH, 2020, 23 : S20 - S20
  • [38] DO ORPHAN DRUGS LACK EVIDENCE IN HEALTH TECHNOLOGY ASSESSMENTS COMPARED TO NON- ORPHAN DRUGS?
    Dittrich, K.
    Klusmeier, N.
    Kubinski, M.
    Loepmeier-Roeh, Jf
    Kossow, S.
    Kulp, W.
    VALUE IN HEALTH, 2024, 27 (12)
  • [39] Innovation and drugs price and reimbursement: a comparison between Italy and the other major EU countries
    Jommi, Claudio
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2015, 2 (03) : 117 - 124
  • [40] REIMBURSEMENT STRATEGIES OF FIRST-IN-CLASS DRUGS FOR TYPE 2 DIABETES MELLITUS IN HEALTH TECHNOLOGY ASSESSMENT IN AUSTRALIA: A QUALITATIVE REVIEW
    Xuan, J.
    Cheng, Y.
    Xu, W.
    Hu, X.
    Tan, B.
    Li, W.
    Chen, L.
    VALUE IN HEALTH, 2020, 23 : S515 - S516
12345